Medtronic's novel spinal cord stimulator shows long-term benefit relieving back pain

• Medtronic (NYSE:MDT) announces positive 12-month results from a randomized 250-subject trial comparing its DTM Spinal Cord Stimulation (SCS) device to conventional SCS therapy with its Intellis system for the treatment of back pain.
• At month 12, the responder rate (at least 50% pain relief) for DTM SCS was 84% versus 51% for Intellis. DTM SCS also demonstrated its superiority as measured by the proportion of patients experiencing profound back pain relief (at least 80% pain relief), 69% vs. 35%.
• The study met the primary endpoint at month 3 which was sustained at month 12.
• The company acquired the DTM SCS device, which employs a novel SCS waveform called Differential Target Multiplexed, via its takeover of privately held Stimgenics in January.
• Management will host a webinar today at 1:00 pm ET to discuss the results.
• https://seekingalpha.com/news/3623632-medtronics-novel-spinal-cord-stimulator-shows-long-term-benefit-relieving-back-pain